DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,492,681 B2 Aydt Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,492,681 B2 Aydt Et Al USOO9492681 B2 (12) United States Patent (10) Patent No.: US 9,492,681 B2 Aydt et al. (45) Date of Patent: Nov. 15, 2016 (54) DEVICE AND METHOD FOR TREATMENT (2013.01); A61N 2005/0656 (2013.01); A61N OF CELLS AND CELL TISSUE 2005/0659 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0662 (2013.01); HOIL (75) Inventors: Ewald Aydt, Rossdorf (DE); Herwig 51/502 (2013.01); HOIL 5 1/5032 (2013.01) Buchholz, Frankfurt am Main (DE); (58) Field of Classification Search Junyou Pan, Frankfurt am Main (DE) CPC ................... A61N 2005/0652: A61N 5/0616: A61N 5/062 (73) Assignee: Merck Patent GmbH, Darmstadt (DE) USPC ........................................ 607/88, 89: 604/20 (*) Notice: Subject to any disclaimer, the term of this See application file for complete search history. patent is extended or adjusted under 35 U.S.C. 154(b) by 432 days. (56) References Cited (21) Appl. No.: 13/985,209 U.S. PATENT DOCUMENTS 2005/O1491.50 A1* 7/2005 McDaniel ............ A61N 5,0616 (22) PCT Fed: Jan. 16, 2012 607/88 2010.013795.0 A1 6, 2010 McDaniel (86) PCT No.: PCT/EP2012/OOO156 (Continued) S 371 (c)(1), (2), (4) Date: Aug. 13, 2013 FOREIGN PATENT DOCUMENTS JP 2007-518452. A 7/2007 (87) PCT Pub. No.: WO2O12A1101.78 WO WO-2010/078581 A1 T 2010 PCT Pub. Date: Aug. 23, 2012 (Continued) Prior Publication Data (65) OTHER PUBLICATIONS US 2013/0324909 A1 Dec. 5, 2013 International Preliminary Report on Patentability for PCT/EP2012/ (30) Foreign Application Priority Data 000156, Aug. 21, 2013. International Search Report for PCT/EP2012/000156 mailed Mar. Feb. 14, 2011 (EP) ..................................... 11 OO1174. 22, 2012. (51) Int. C. Primary Examiner — William Thomson A61N L/00 (2006.01) Assistant Examiner — Jeffrey Lipitz A6IN 5/06 (2006.01) (74) Attorney, Agent, or Firm — Drinker Biddle & Reath A6DF 9/008 (2006.01) LLP HOIL 5L/50 (2006.01) (52) U.S. C. (57) ABSTRACT CPC ............. A61N 5/06 (2013.01); A61F 9/00834 The present invention relates to a cells and cell tissue (2013.01); A61N 5/062 (2013.01); A61N treatment device and use thereof. 5/0616 (2013.01); HOIL 51/50 (2013.01); A61N 2005/0653 (2013.01); A61N 2005/0654 18 Claims, 5 Drawing Sheets Al Cathode El Composition PEDOT:PSS TO anode Substrate US 9,492,681 B2 Page 2 (56) References Cited FOREIGN PATENT DOCUMENTS U.S. PATENT DOCUMENTS WO WO-2011,069590 A1 6, 2011 WO WO-2011110275 A2 9, 2011 2010/0179469 A1* 7, 2010 Hammond ........... A61N 5,0603 604/20 2010/0234792 A1 9/2010 Dacey, Jr. et al. * cited by examiner U.S. Patent Nov. 15, 2016 Sheet 1 of 5 US 9,492,681 B2 Figure 1 a Al Cathode EL Composition PEDOT:PSS TO anode Substrate Figure 1b Substrate Figure 1C - - - - - - - - 106 - - - - - - - - 105 - - - - - - - - - - 104 - - - - - - - - - - 103 - - - - - - - - - - 102 - - - - - - - - - - 101 Figure 2 Substrate Coating EML Buffer layer - r. -- - - - Interlayer Cathod 2:3: -drE. en 3. 3. Cap TO 3 Contact pad 1 Contact pad2 U.S. Patent NOV. 15, 2016 sheet 2 of us 9492,681 B. Figure 3 U.S. Patent Nov. 15, 2016 Sheet 3 of 5 US 9,492,681 B2 Fig. 4 U.S. Patent Nov. 15, 2016 Sheet 4 of 5 US 9,492,681 B2 Fig. 5 U.S. Patent Nov. 15, 2016 Sheet S of 5 US 9,492,681 B2 Fig. 6 US 9,492,681 B2 1. 2 DEVICE AND METHOD FOR TREATMENT the body which is to be treated. That area is then exposed to OF CELLS AND CELLTISSUE light of a Suitable frequency and intensity to activate the photopharmaceutical. A variety of photopharmaceutical CROSS-REFERENCE TO RELATED agents are currently available. For example there are topical APPLICATIONS agents such as 5-aminolevulinic acid hydrochloride (Craw ford Pharmaceuticals), methylaminolevulinic acid (Met This application is a national stage application (under 35 fix(R), Photocure). There are also injectable drugs used pri U.S.C. S371) of PCT/EP2012/000156, filed Jan. 16, 2012, marily for internal malignancies, including Photofin R (from which claims benefit of European application 11001174.9, AXcan) and Foscan R (from Biolitech Ltd). Often, the drug filed Feb. 14, 2011. 10 is applied in a non-active form that is metabolized to a The present invention relates to a cells and/or cell tissue light-sensitive photopharmaceutical. treatment device, to a kit of parts for treatment of cells In photodynamic therapy, the primary technique for Sup and/or cell tissue, to use of Such a device or kit of parts and plying light to the photopharmaceutical is to project light of to a method for treatment of cells and cell tissue. a suitable wavelength from standalone light sources such as Phototherapy (also called light therapy) can be employed 15 lasers or filtered arc lamps. These sources are cumbersome in a wide range of therapeutic diseases and/or cosmetic (also and expensive, and are therefore only Suitable for use in called aesthetic) conditions. Phototherapy by either employ hospitals. This leads to inconvenience for the patient, and ing LED or laser as light source has already been used to high cost for the treatment. High light irradiances are needed treat wounds, injuries, neck pain, osteoarthritis, the side in order to treat an acceptable number of patients per day effects of chemotherapy and radiotherapy, for instance. (for the treatment to be cost effective) and to avoid unduly The treatment or prophylaxis of acne may have both inconveniencing the patient. therapeutic and cosmetic components, depending on the To date, phototherapy and PDT is dominated by the degree of the condition. The same accounts for psoriasis, application of large light sources being uncomfortable for atopic dermatitis and other diseases and/or conditions. Many patients leading to low compliance. Many of the devices diseases and conditions are associated with apparent impli 25 which are currently in use are only applicable stationary and cations which are often represented by a change in the require the control of medical professionals, e.g. in hospital visibility of a subject’s skin, for instance. These cosmetic or or in doctor's Surgery. Furthermore, many of the light aesthetic changes can often lead to psychological modifica Sources currently used irradiate large areas of the Subject to tions resulting, at least in part, in serious diseases. be treated, even if only a fraction of it should have been Some conditions or diseases may have an emphasis on 30 irradiated which may lead to unwanted side effects. cosmetic components. Some of these are selected from WO 98/46130 and U.S. Pat. No. 6,096,066 disclose arrays anti-ageing, anti-wrinkle, the prevention and/or therapy of of LEDs for use in photodynamic therapy. The small LED acne and vitiligo. Sometimes, therapeutic elements may also Sources taught therein result in uneven light incident on the play a role. patient. Fabrication of arrays is complicated because of the In both cosmetics and medicine the skin is the main target 35 large number of connections required. The devices shown to be irradiated, but other targets of the human or animal therein are designed for hospital treatment. body can also be accessed by phototherapy. These targets GB 2360461 discloses a flexible garment which uses a include, but are not limited to, the eye, wounds, nails, and conventional photodynamic therapy light source to produce internal parts of the body. Light can also be used in order to light which is then transmitted through optical fibres. As facilitate or Support disinfection of wounds, beverages, 40 Such light sources are heavy, the device is not ambulatory nutrition, for example. and is limited to hospital use. One effect of phototherapy is the stimulation of metabo U.S. Pat. No. 5,698,866 discloses a light source using lism in the mitochondria. Certain wavelengths of light over-driven inorganic LEDs. The resulting light output is not stimulate cytochrome c oxidase, an enzyme which is respon even. A heat-sinking mechanism is required, and the device sible for the production of the essential cellular energy in the 45 is suitable only for hospital treatment. form of adenosine triphosphate (ATP). ATP is required for WO 93/21842 discloses light sources using inorganic cellular energy transfer in order to drive thermodynamically LEDs. Although transportable, the device is not suitable for unfavoured biochemical reactions and as cellular energy ambulatory use by a patient at home and clinical treatment storage. ATP can also act as signal molecule in order to is envisaged. modulate other biochemical molecules (e.g. reactive oxygen 50 According to U.S. Pat. No. 6,283,956 LEDs are used for species and nitric oxide) that lead to ageing and cell death reduction, elimination or stimulation of hair growth. (oxidative stress). After phototherapy, the cells show an An essential prerequisite for the application of light in the increased metabolism, they communicate better and they fields mentioned above is the device. The commercial avail survive stressful conditions in a better way. able systems nowadays are mostly based on lasers. How Such principle can be applied for medicinal therapeutic 55 ever, theses systems are hospital based, i.e. stationary and cosmetic applications, such as wound healing, connec devices. In order to reduce costs and to increase convenience tive tissue repair, tissue repair, prevention of tissue death, as well as compliance a portable home-use technology is relief of inflammation, pain, acute injuries, chronic diseases, required. In fact, Some research has been devoted in this metabolic disorders, neurogenic pain and seasonal effect direction. disorders. 60 Rochester et al. disclosed in GB 24082092a flexible Another area of the application of light is the treatment of medical light Source including flexible light emitting diodes various cancers.
Load more

Recommended publications
  • Pathogenesis of Rosacea Anetta E
    REVIEW Pathogenesis of Rosacea Anetta E. Reszko, MD, PhD; Richard D. Granstein, MD Rosacea is a chronic, common skin disorder whose pathogenesis is incompletely understood. An inter- play of multiple factors, including genetic predisposition and environmental, neurogenic, and microbial factors, may be involved in the disease process. Rosacea subtypes, identified in the recently published standard classification system by the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, may in fact represent different disease processes, and identifying subtypes may allow investigators to pursue more precisely focused studies. New developments in molecular biology and genetics hold promise for elucidating the interplay of the multiple factors involved in the pathogen- esis of rosacea, as well as providing the bases for potential new therapies. osacea is a common, chronic skin disorder and secondary features needed for the clinical diagnosis primarily affecting the central and con- of rosacea. Primary features include flushing (transient vex areas of COSthe face. The nose, cheeks, DERM erythema), persistent erythema, papules and pustules, chin, forehead, and glabella are the most and telangiectasias. Secondary features include burn- frequently affected sites. Less commonly ing and stinging, skin dryness, plaque formation, dry affectedR sites include the infraorbital, submental, and ret- appearance, edema, ocular symptoms, extrafacial mani- roauricular areas, the V-shaped area of the chest, and the festations, and phymatous changes. One or more of the neck, the back, and theDo scalp. Notprimary Copy features is needed for diagnosis.1 The disease has a variety of clinical manifestations, Several authors have theorized that rosacea progresses including flushing, persistent erythema, telangiecta- from one stage to another.2-4 However, recent data, sias, papules, pustules, and tissue and sebaceous gland including data on therapeutic modalities of various sub- hyperplasia.
    [Show full text]
  • (2006.01) Published: A61K9/08
    ) ( (51) International Patent Classification: Published: A61K 31/05 (2006.01) A61P 1 7/02 (2006.01) — with international search report (Art. 21(3)) A61K9/08 (2006.01) A61P29/00 (2006.01) A61P 1 7/00 (2006.01) (21) International Application Number: PCT/AU20 19/05005 1 (22) International Filing Date: 24 January 2019 (24.01.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2018900226 24 January 2018 (24.01.2018) AU 62/621,225 24 January 2018 (24.01.2018) US 2018903600 25 September 2018 (25.09.2018) AU 62/736,052 25 September 2018 (25.09.2018) US (71) Applicant: BOTANIX PHARMACEUTICALS LTD [AU/AU]; 63 Aberdeen Street, Northbridge, Western Aus¬ tralia 6003 (AU). (72) Inventors: CALLAHAN, Matthew; One Kew Place, 150 Rouse Boulevard, Navy Yard Corporate Center, Philadel¬ phia, Pennsylvania 191 12 (US). THURN, Michael; 912 Kangaroobie Road, Kangaroobie, NSW 2800 (AU). (74) Agent: WRAYS PTY LTD; Level 7, 863 Hay Street, Perth, Western Australia 6000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Curriculum Vitae Clay J. Cockerell, M.D. Home
    CURRICULUM VITAE CLAY J. COCKERELL, M.D. HOME ADDRESS 4312 Arcady Avenue Dallas, Texas 75205 (214) 522-2610 WORK ADDRESS Cockerell & Associates-Dermpath Diagnostics Dermatopathology Laboratories 2330 Butler Street, Suite 115 Dallas, Texas 75235 Phone: (214) 530-5200, (800) 309-0000 Fax: (214) 530-5232 BIRTH DATE AND PLACE September 16, 1956, Houston, Texas MARITAL STATUS Married - Brenda West Cockerell Two children - Charles West Cockerell & Lillian Allene Cockerell COLLEGE EDUCATION 1974 – 1977 Texas Tech University Majors: Zoology, Microbiology, Chemistry No degree - entered Medical School via Early Decision Program GRADUATE EDUCATION 1977 - 1981 Baylor College of Medicine Degree - M.D. with honors, June 1981 POSTGRADUATE EDUCATION 1981-1982 Internship, Internal Medicine University of Washington Affiliated Hospitals, Seattle, Washington 1982-1985 Residency, Dermatology New York University Medical Center, New York, New York 1984-1985 Chief Resident, Dermatology New York University Medical Center, New York, New York 1985-1986 Fellowship, Dermatopathology New York University Medical Center, New York, New York OTHER TRAINING Sloan-Kettering Memorial Hospital, Pathology New York, New York Part-time clinical observer July 1986 - January 1987 Clay J. Cockerell, M.D. Updated 1/15/2018 Page 2 ACADEMIC APPOINTMENTS University of Texas Southwestern Medical Center Assistant Professor, Dermatology and Pathology, September 1988 - September 1992 Associate Professor, Dermatology and Pathology, September 1992 - September 1993 Clinical Associate Professor,
    [Show full text]
  • A Dissertation on CLINICO EPIDEMIOLOGICAL STUDY of FACIAL DERMATOSES AMONG ADULTS
    A Dissertation on CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS Dissertation submitted to THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY CHENNAI-600032 With partial fulfillment of the requirements for the award of M.D.DEGREE IN DERMATOLOGY, VENEREOLOGY AND LEPROLOGY (BRANCH - XX) REG. No. 201730201 COIMBATORE MEDICAL COLLEGE AND HOSPITAL COIMBATORE MAY 2020 DECLARATION I Dr . MANIVANNAN . M solemnly declare that the dissertation entitled “CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS ” is a bonafide work done by me at Coimbatore Medical College Hospital during the year June 2018 to May 2019 under the guidance & supervision of Dr. M. KARUNAKARAN M.D., (DERM) Professor& Head of Department, Department of Dermatology, Coimbatore Medical College & Hospital. The dissertation is submitted to Dr. MGR Medical University towards partial fulfillment of requirement for the award of MD degree branch XX Dermatology, Venereology and Leprology. PLACE: Dr. MANIVANNAN .M DATE: CERTIFICATE This is to certify that the dissertation entitled “CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS” is a bonafide original work done by Dr. MANIVANNAN.M. Post graduate student in the Department of Dermatology, Venereology and Leprology, Coimbatore Medical College Hospital, Coimbatore under the guidance of Dr. M. KARUNAKARAN M.D., (DERM), Professor and HOD of Department, Department of Dermatology, Coimbatore Medical College Hospital, Coimbatore in partial fulfillment of the regulations for the Tamilnadu DR.M.G.R Medical University, Chennai towards the award of MD., degree (Branch XX.) in Dermatology, Venereology and Leprology. Date : GUIDE Dr. M. KARUNAKARAN M.D., (DERM) Professor & HOD, Department of Dermatology, Coimbatore Medical College & Hospital. Date : Dr.
    [Show full text]
  • Dermatology 101: from Acne to Zebras and the Pearls in Between
    Dermatology 101: From Acne to Zebras and the Pearls in Between Dr Kyle Cullingham, BA, BSc, MSc, MD, FRCPC Dermatologist Skinsense Dermatology, Saskatoon,SK Assistant Professor University of Saskatchewan Disclosures Speaker: Dr Kyle Cullingham Relationships with commercial interests: Speakers Bureau/Honoraria: Abbvie, Allergan, Celgene, LEO Consulting Fees: Abbvie, Celgene, Galderma, Janssen, LEO, Novartis Conflict of Interest Declaration: Nothing to Disclose Presenter: Dr. Kyle Cullingham Title of Presentation:Dermatology for GPs I have no financial or personal relationship related to this presentation to disclose. Objectives Discuss some common dermatological concerns – focus on recognition, management, what’s new and pearls. Acne Clinical pearls Rosacea Psoriasis Eczema Interspersed with interesting real Dermatology cases with common pitfalls, red flags, or learning points. Time for questions/comments Acne disorder of the pilosebaceous unit affects certain areas of the body: face > trunk >> buttocks manifests during adolescence, but can occur at any stage of life comedones, papulopustules, nodules, cysts scarring can follow Epidemiology acne affects approximately 85% of adolescents onset during puberty (10-19 y/o); may appear after age 25 more severe in men higher incidence in caucasians and indigenous population inheritance: multifactorial; most patients with cystic acne have parental history of severe acne Pathogenesis Corneocyte Sebum Propionibacterium acnes Inflammatory cell Drugs Diet Recent JAAD review
    [Show full text]
  • Kazlouskaya V
    MINISTRY OF HEALTH OF REPUBLIC OF BELARUS GOMEL STATE MEDICAL UNIVERSITY V. V. Kazlouskaya SELECTED LECTURES ON DERMATOLOGY Manual for foreign medical students Gomel GSMU 2008 УДК 616.5 (075.8)=20 ББК 55.8 К 59 Рецензеты: заведующий кафедрой дерматовенерологии УО «Витебский государственный медицинский университет», доктор медицинских наук, профессор В. П. Адаскевич; заведующий кафедрой поликлинической терапии и общеврачебной практики с курсом дерматовенерологии УО «Гомельский государственный медицинский университет», кандидат медицинских наук, доцент Э. Н. Платошкин. Козловская, В. В. К 59 Курс лекций по дерматологии: учеб.-метод. пособие для студентов- медиков = Selected Lectures on Dermatology: manual for foreign medical students / В. В. Козловская. — Гомель: Учреждение образования «Го- мельский государственный медицинский университет», 2008. — 160 с. ISBN 978-985-506-210-4 Учебно-методическое пособие «Selected Lectures on Dermatology» представляет собой курс лекций по дерматологии, предназначенный для иностранных студентов 3 курса, обучающихся на английском языке. Лекции составлены в соответствии с типовой учебной программой и содержат основные разделы цикла дерматология. Утверждено и рекомендовано к изданию Центральным учебным научно- методическим советом учреждения образования «Гомельский государственный медицинский университет» 20 ноября 2008 г., протокол № 11. УДК 616.5 (075.8) ББК 55.8 ISBN 978-985-506-210-4 © Учреждение образования «Гомельский государственный медицинский университет», 2008 2 Abbreviations Used in the Book AA
    [Show full text]
  • UC Davis Dermatology Online Journal
    UC Davis Dermatology Online Journal Title Otophyma: a rare benign clinical entity mimicking leprosy Permalink https://escholarship.org/uc/item/41p4q5xq Journal Dermatology Online Journal, 21(3) Authors Shuster, Marina McWilliams, Ashley Giambrone, Danielle et al. Publication Date 2015 DOI 10.5070/D3213024280 Supplemental Material https://escholarship.org/uc/item/41p4q5xq#supplemental License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 21 Number March 2015 Photo vignette Otophyma: a rare benign clinical entity mimicking leprosy Marina Shuster BA1, Ashley McWilliams BS2, Danielle Giambrone BS3, Omar Noor MD3, Jisun Cha MD3 Dermatology Online Journal 21 (3): 22 1Harvard Medical School 2Virginia Commonwealth University School of Medicine 3Rutgers- Robert Wood Johnson Medical School Correspondence: Danielle Giambrone Department of Dermatology Rutgers- Robert Wood Johnson Medical School 1 World’s Fair Drive Somerset, NJ 08873 Email: [email protected] Phone: 609-220-7710 Abstract Otophyma is a rare condition characterized by edematous deformation of the ear that is considered to be the end-stage of an inflammatory process such as rosacea and eczema. This report illustrates a case in an elderly male, originally thought to have leprosy. Biopsy revealed a nodular infiltration of inflammatory cells around adnexal structures and an intraepidermal cyst. No acid-fast organisms were identified. We present a patient who is of a different ethnic group than usually seen with this disease and provide a review of the clinical presentation, histopathological features, and management of this rare condition. Keywords: Otophyma, Leprosy, Rhinophyma, Rosacea Case synopsis A 62-year-old Filipino male presented for evaluation of his grossly enlarged ears.
    [Show full text]
  • Internal Medicine In-Review Study Guide
    INTERNAL MEDICINE IN-REVIEW STUDY GUIDE Companion to the Online Study System InReviewIM.com Senior Editor Norman H. Ertel, MD Associate Editors James M. Horowitz, MD Miguel A. Paniagua, MD, FACP Available through support from the makers of Powered by © 2013 Educational Testing & Assessment Systems. All Rights Reserved. This document contains proprietary information, images, and marks of Educational Testing & Assessment Systems. No reproduction or use of any portion of the contents of these materials may be made without the express written consent of Educational Testing & Assessment Systems. If you feel you have obtained this illegally, please contact Educational Testing & Assessment Systems immediately. The questions and answers, statements or opinions contained in this Study Guide or Web Site have not been approved by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., the makers of TYLENOL®. McNeil will not be held responsible for any questions and answers, statements or opinions, contained in the Study Guide, Web Site, or any supplementary materials. Any questions about the content of Internal Medicine In-Review should be directed to Educational Testing and Assessment Systems, Inc. which controls the content and owns all copyrights in the materials. The developments in medicine are always changing, from clinical experiences, new research, and changes in treatment and drug therapy. The Internal Medicine In-Review team use reasonable efforts to include information that is complete and within accepted standards at the time of publication. However, the faculty, authors, publisher, nor any other party who has been involved in the preparation of Internal Medicine In-Review make representations, warranties, or assurances as to the accuracy, currency, or completeness of the information provided.
    [Show full text]
  • Triggers and Treatment of Rosacea
    MedicineToday 2015; 16(1): 34-40 PEER REVIEWED FEATURE 2 CPD POINTS Triggers and treatment of rosacea SHIEN-NING CHEE MB BS, MMed PATRICIA LOWE MB BS, MMed, FACD Key points Rosacea is a common chronic inflammatory skin condition that can • Rosacea is a common lead to significant facial changes, ocular involvement and decreased condition characterised by quality of life. Its cause is multifactorial and not completely understood. flushing, erythema, inflammatory lesions and Treatment aims to control, but not cure, the disease. telangiectasia. • The cause is multifactorial osacea is a common chronic inflam­ PATHOPHYSIOLOGY and not completely matory skin disease primarily affecting The pathophysiology of rosacea is multifactorial understood: genetics, the facial convexities. It is characterised and not completely understood. At present, neurovascular dysregulation Rby vascular lability, leading to flushing, rosacea is thought of as a complex inflammatory and infections may be telangiectasia and fixed erythema, and cuta­ disorder arising in genetically predisposed involved. neous inflammation, manifesting as papules, individuals. • Diagnosis of rosacea is pustules and lymphoedema. Although not based on clinical findings, life ­threatening, rosacea may have a significant Genetics although investigations may impact on a patient’s self­esteem and quality of Rosacea often affects multiple family members. be required to exclude life. Early diagnosis and treatment will reduce Recent analyses have found distinct genetic differential diagnoses. morbidity. profiles for each rosacea subtype, with expres­ • Treatment is tailored to the sion of more than 500 different genes compared individual and aims to EPIDEMIOLOGY with healthy skin.3 The skin of patients with control symptoms and signs, Estimated prevalence rates of rosacea range from rosacea has been found to be dry and acidic, but not cure the disease.
    [Show full text]
  • Acne and Acneiform Related Eruptions
    Acne and acneiform related eruptions Objectives : ➢ To know the multiple pathogenetic mechanisms causing acne ➢ To recognize the clinical features of acne. ➢ To differentiate acne from other acneiform eruptions such as rosacea. ➢ To prevent acne scars and treat acne efficiently. ➢ To recognize the clinical features of rosacea, it’s variable types, differential diagnosis and treatment ➢ To recognize the features of perioral dermatitis, differential diagnosis and treatment. ➢ To recognize the features of hidradenitis suppurativa and treatment Done by: Sadeem Alqahtani & Khawla Alammari Revised by: Lina Alshehri. [ Color index : Important | Notes | Extra ] ​ ​ ​ ​ ​ ​ ​ ACNE VULGARIS Definition/prevalence: ● Multifactorial disease of pilosebaceous unit that affects both males and females. ​ ​ ● It is the most common dermatological disease. ● Mostly prevalent between 12-24 yrs. Affects 8% between 25-34, 4% between 35-44. Pathogenesis: 1- Ductal cornification and occlusion (micro-comedo). 2- Increased sebum secretion (Seborrhoea). 3- Ductal colonization with propionibacterium acnes. 4- Rupture of sebaceous gland and inflammation. Specialized terms: ● Microcomedone: Hyperkeratotic plug made of sebum and keratin in follicular canal. ​ ● Closed Comedo (Whitehead): Closed follicular orifice, accumulation of sebum and keratin ​ ​ ​ ​ ● Open Comedo (Blackhead): Opened follicular orifice packed with melanin and oxidized lipids ​ ​ ​ ​ ● We categorize acne (depending on the type of lesion) into: mild, moderate and severe. Comedones are considered mild. Nodules, cysts, pustules (can lead to scarring or hyperpigmentation) are ​ ​ considered moderate to severe. ​ ​ ● Our pathognomonic lesion is comedone, you can NOT diagnose acne without having comedones, if you do not have comedones THIS IS NOT ACNE! Clinical features: Acne lesions are divided into: ● Inflammatory (papules,pustules,nodules,cyst). ● Non inflammatory (open, closed comedones).
    [Show full text]
  • Rhinophyma: Practical and Safe Treatment with Trichloroacetic Acid
    RevSurgicalV6N4-ingles_RevistaSurgical&CosmeticDermatol 26/03/15 08:49 Page 368 368 New Techniques Rhinophyma: practical and safe treatment with trichloroacetic acid Rinofima: tratamento prático e seguro com ácido triclcoroacético Author Neide Kalil Gaspar1 Antonio Pedro Andrade Gaspar2 Marcia Kalil Aidê3 1 Dermatologist Physician; Emeritus Professor at the Universidade Federal Fluminense (UFF) – Niterói (RJ), Brazil 2 Dermatologist Physician; Assistant ABSTRACT Professor, UFF The authors introduce a method for the treatment of different intensities and scales of rhi- nophyma, with trichloroacetic acid. This is a safe process, created and performed by the 3 Dermatologist Physician at private practice - Niterói (RJ), Brazil authors for five decades, with an absence of descriptions of adverse effects. Keywords: trichloroacetic acid; rhinophyma; therapeutics. RESU MO Apresentamos método de tratamento com ácido tricloroacético para casos de rinofima de diferentes intensidades e extensões. Trata-se de processo seguro, que criamos há cinco décadas e desde então vimos executando, sem nenhum efeito adverso. Palavras-chave: ácido tricloroacético; rinofima; terapêutica. INTRODUCTION Rhinophyma is a disfiguring and progressive disorder of the nasal skin, characterized by hyperplasia of the sebaceous glands with occlusion of the ducts and dermal fibrosis, typically affecting middle aged Caucasian men. This process occurs most commonly in rosacea patients Correspondence: and can affect the frontal region (metophyma) or, more rarely, Neide Kalil Gaspar R. Erotides de Oliveira, 36/301 – Icarai the ears (otophyma), eyelids (blepharophyma), or the mentum Cep: 24230-230 - Niterói (RJ), Brazil (gnatophyma). E-mail: [email protected] Its development is progressive and deforming, and in some patients there can be intermittent inflammation, which may result in scars and fibrous tissue.
    [Show full text]
  • The Effect of Probiotics on Skin
    December 2014 The effect of probiotics on skin Probiotics in dermatology — from theory to enterprise ACADEMIC CONSULTANCY TRAINING Group 1457 Bob van den Berg Jiang Chang Aafke Duizendstra Renate Jansen Ana Jimena Pacheco Gutierrez Tian Zhao Coach: Carel Weijers Content coach: Willemien Lommen Commissioner: Skinwiser, Dr Jetske Ultee & Matthijs Boog Ana Jimena Pacheco Gutierrez [email protected] 0626667543 Stichting Skinwiser Matthijs Boog ([email protected]) Maasstraat 11 3016 DB Rotterdam Source image: “ The trillions of microbes in and on our bodies are key to understanding our health ” Follow Up on AO+ Living Bacterial Skin Tonic - Allergies & Your Gut (Accessed December 5, 2014) Disclaimer This report (product) is produced by students of Wageningen University as part of their MSc- programme. It is not an official publication of Wageningen University or Wageningen UR and the content herein does not represent any formal position or representation by Wageningen University. Part of MSc course Academic Consultancy Training (9 ECTS) Copyright © 2014 All rights reserved. No part of this publication can be reproduced or distributed in any form or by any means, without the prior consent of the authors. i The effect of probiotics on skin ACT group 1457 Team logo of ACT group 1457, all rights reserved “ Staphylococcus epidermidis protects our skin from the invading pathogens ” ii Executive summary This project was commissioned by Skinwiser to examine whether probiotics can have a positive effect on the skin. We assessed if topical application of probiotics can improve healthy or affected skin. The skin conditions included are rosacea, acne and atopic dermatitis. First, literature about healthy skin, skin conditions and (gut) probiotics was studied.
    [Show full text]